Free Trial
NASDAQ:SRDX

Surmodics Q2 2025 Earnings Report

Surmodics logo
$29.16 +0.08 (+0.28%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$29.16 0.00 (0.00%)
As of 06/13/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Surmodics EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.06
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Surmodics Revenue Results

Actual Revenue
$28.09 million
Expected Revenue
$32.23 million
Beat/Miss
Missed by -$4.14 million
YoY Revenue Growth
N/A

Surmodics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, April 30, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Surmodics' Q3 2025 earnings is scheduled for Wednesday, July 30, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Surmodics Earnings Headlines

New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
A Look at Surmodics's Upcoming Earnings Report
See More Surmodics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surmodics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surmodics and other key companies, straight to your email.

About Surmodics

Surmodics (NASDAQ:SRDX), together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

View Surmodics Profile

More Earnings Resources from MarketBeat